Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty Drugsharvard pilgrim prior auth drug coverage update | …
    Ask Trek AI about this page
    Currentharvard pilgrim health carePolicy N/A

    Prior Authorization Medical Necessity Guidelines — Partial drug list

    Customize your policy alerts

    Sign up for all harvard pilgrim health care policy alerts

    Know when harvard pilgrim health care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Portion of Harvard Pilgrim Health Care prior authorization medical necessity guidelines listing specialty and pharmacy drugs, their covered indications, prescriber and prerequisite therapy requirements, and coverage durations for affected products. Affects prescribers requesting PA for the listed drugs and health plan administrators.

    Policy Summary
    Payerharvard pilgrim health care
    PolicyPrior Authorization Medical Necessity Guidelines — Partial drug list
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit documented diagnosis and required prior-therapy or mutation testing evidence when requesting prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    20+products listed in this excerpt
    2 yrstypical coverage duration stated
    specialistprescriber restrictions

    Product-specific Coverage Criteria

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Abilify Mycite — Initial coverage criteria

    Product-specific coverage conditions (examples from excerpt):

    Abilify Mycite: Member must have a documented diagnosis of bipolar I disorder, major depressive disorder, or schizophrenia AND documentation of worsening symptoms with oral aripiprazole AND prescribing physician must be a psychiatrist.

    Coverage duration 2 years; prerequisite Part D drug required.

    Adalimumab products — Coverage criteria

    Adalimumab product criteria (representative):

    Adalimumab indications: Member must have a documented diagnosis specific to the condition (examples: active ankylosing spondylitis, Crohn's disease, moderately to severely active ulcerative colitis, hidradenitis suppurativa, moderate-to-severe plaque psoriasis with failure/intolerance to specified topical therapies, rheumatoid arthritis with trial/failure/intolerance to one conventional therapy, PJIA with trial/failure/intolerance to one conventional therapy).

    Prescribed by or in consultation with appropriate specialist (dermatologist, gastroenterologist, ophthalmologist, or rheumatologist); coverage duration 2 years; prerequisite Part D drug may be required as specified.

    Wakefulness agents — Coverage criteria

    Armodafinil/Modafinil criteria:

    Armodafinil / Modafinil: Member must have a documented diagnosis of narcolepsy OR excessive sleepiness associated with obstructive sleep apnea OR shift-work sleep disorder.

    Excluded: generalized fatigue, jet lag, or sleep-deprivation not associated with a covered diagnosis; coverage duration 2 years; no prerequisite Part D drug required.

    Cometriq (progressive metastatic medullary thyroid cancer)

    Products with specific required medical information

    Cometriq/Caprelsa (cabozantinib): Member must have a documented diagnosis of symptomatic or progressive medullary thyroid cancer that is unresectable locally advanced or metastatic.

    Prescribing physician must be an endocrinologist or oncologist; coverage duration 2 years; no prerequisite Part D drug required.

    Carglumic acid (NAGS deficiency)

    Carglumic Acid: Member must have a documented diagnosis of chronic hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency OR acute hyperammonemia due to NAGS deficiency when used as adjunctive therapy.

    Coverage duration 2 years; no prerequisite Part D drug required.

    Cayston (CF with Pseudomonas)

    Cayston: Member must have a documented diagnosis of cystic fibrosis AND evidence of Pseudomonas aeruginosa in the lungs.

    Coverage duration 2 years; no prerequisite Part D drug required.

    Copiktra (relapsed/refractory CLL/SLL)

    Copiktra: Member must have documented relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) AND have received at least two prior therapies.

    Prescribing physician must be a hematologist or oncologist; criteria requires use of a prerequisite Part D drug; coverage duration 2 years.

    Cosentyx (various inflammatory indications)

    Cosentyx indications: Member must meet indication-specific diagnosis such as active ankylosing spondylitis; moderate-to-severe plaque psoriasis with failure/intolerance to specified topical therapies; psoriatic arthritis; non-radiographic axial spondyloarthritis with objective inflammation after trial/failure of two NSAIDs; enthesitis-related arthritis with NSAID trial/failure; hidradenitis suppurativa as specified.

    Prescribed by or in consultation with a dermatologist or rheumatologist; coverage duration 2 years; prerequisite Part D drug required.

    Cotellic (BRAF-mutant melanoma / histiocytic neoplasm)

    Cotellic: Member must have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation when used in combination with vemurafenib OR have histiocytic neoplasm when used as monotherapy.

    Not indicated for wild-type BRAF melanoma; prescriber must be an oncologist; coverage duration 2 years; no prerequisite Part D drug required.

    Cresemba (invasive fungal infections)

    Cresemba (isavuconazole): Member must have a documented diagnosis of invasive aspergillosis OR invasive mucormycosis.

    Coverage duration 1 year; no prerequisite Part D drug required.

    BCR-ABL inhibitors (dasatinib, danziten)

    Dasatinib / Danziten: Member must meet the agent-specific CML or Ph+ ALL diagnosis (e.g., newly diagnosed Ph+ CML in chronic phase OR chronic/accelerated/blast phase Ph+ CML resistant/intolerant to prior therapy OR Ph+ ALL with resistance/intolerance to prior therapy); pediatric indications as specified.

    Prescriber may be hematologist/oncologist; coverage duration 2 years; some agents require prerequisite Part D drug.

    Daurismo (glasdegib) - newly diagnosed AML

    Daurismo (glasdegib): Member must have newly diagnosed acute myelogenous leukemia (AML) and the drug is being used with low-dose cytarabine AND the member is either ≥75 years of age OR has comorbidities that make them ineligible for intensive induction chemotherapy.

    Prescribing physician must be a hematologist or oncologist; coverage duration 2 years; no prerequisite Part D drug required.

    Diacomit and Doptelet (neurology/hematology indications)

    Diacomit / Doptelet: Diacomit: seizures associated with Dravet syndrome when used concurrently with clobazam. Doptelet: thrombocytopenia associated with chronic liver disease scheduled for a procedure OR thrombocytopenia due to chronic ITP with insufficient response to prior treatment.

    Diacomit prescriber must be a neurologist; coverage duration 2 years; Doptelet may require a prerequisite Part D drug as specified.

    Droxidopa and Dupixent (various indications)

    Droxidopa / Dupixent: Droxidopa: documented diagnosis of neurogenic orthostatic hypotension. Dupixent: documented diagnosis per indication (e.g., moderate-to-severe atopic dermatitis with trial/failure of topical therapies; moderate-to-severe eosinophilic asthma or OCS-dependent asthma; CRSwNP inadequately controlled; prurigo nodularis; eosinophilic esophagitis; COPD eosinophilic phenotype as add-on; bullous pemphigoid; allergic fungal rhinosinusitis).

    Dupixent not approved for relief of acute bronchospasm or status asthmaticus; Dupixent prescribed by or in consultation with appropriate specialist; coverage duration 2 years; prerequisite Part D drug required for Dupixent.

    Eltrombopag and Emgality

    Eltrombopag / Emgality: Eltrombopag: documented diagnosis of persistent or chronic ITP with insufficient response or intolerance to corticosteroids, immunoglobulins, or splenectomy; severe aplastic anemia as adjunct/after immunosuppressive therapy; thrombocytopenia with chronic hepatitis C. Emgality: documented migraine or episodic cluster headache for initial approval.

    Eltrombopag may require prerequisite Part D drug; Emgality initial approval 6 months then subsequent as indicated; coverage durations vary.

    Empaveli (PNH)

    Empaveli: Initial approval requires documented diagnosis of paroxysmal nocturnal hemoglobinuria (PNH).

    Prescribed by or in consultation with hematology/oncology or nephrology for initial PNH; reauthorization requires demonstrated clinical response; coverage duration 2 years.

    Enbrel (various rheumatologic/dermatologic indications)

    Enbrel: Member must have documented diagnosis per indication (ankylosing spondylitis, moderate-to-severe plaque psoriasis with topical therapy failure, rheumatoid arthritis with trial/failure/intolerance to one conventional therapy, PJIA similarly, psoriatic arthritis).

    Prescribed by or in consultation with dermatologist or rheumatologist; coverage duration 2 years; prerequisite Part D drug required.

    Ensacove (ALK-positive NSCLC)

    Ensacove: Member must have documented diagnosis of locally advanced or metastatic non-small cell lung cancer (NSCLC) with ALK rearrangement AND patient has not previously received an ALK-inhibitor.

    Coverage duration 2 years; approve for continuation of prior therapy where applicable; no prerequisite Part D drug required.

    Epidiolex (epilepsy syndromes)

    Epidiolex: Member must have documented diagnosis of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex.

    Prescribing physician must be a neurologist; coverage duration 2 years; no prerequisite Part D drug required.

    Selected oncology and TSC agents

    Selected oncology and TSC agents: Indication- specific documented diagnosis per product (examples: metastatic basal cell carcinoma recurrent after surgery for Erivedge; ARCC, pNET, TSC-related renal angiomyolipoma and SEGA for everolimus).

    Prescriber specialty varies by product (dermatologist, oncologist, neurologist); coverage generally 2 years; prerequisite Part D drug requirements vary.

    Pirfenidone (IPF)

    Pirfenidone: Member must have a documented diagnosis of idiopathic pulmonary fibrosis (IPF).

    Prescribing physician must be a pulmonologist; coverage duration 2 years; no prerequisite Part D drug required.

    Eucrisa (atopic dermatitis)

    Eucrisa: Initial: documented diagnosis of mild to moderate atopic dermatitis AND trial and failure, contraindication, or intolerance to one prescription-strength topical corticosteroid unless area is sensitive (face, axillae, groin).

    Reauthorization requires positive clinical response; coverage duration 2 years; prerequisite Part D drug required.

    Exkivity, Fasenra, Fintepla

    Exkivity / Fasenra / Fintepla: Exkivity: documented locally advanced or metastatic NSCLC with EGFR exon 20 insertion and progression on/after platinum-based chemotherapy. Fasenra: severe eosinophilic asthma despite inhaled corticosteroid plus an additional controller OR eosinophilic granulomatosis with polyangiitis (EGPA). Fintepla: seizures associated with Dravet syndrome or Lennox-Gastaut syndrome.

    Fasenra prescriber must be an asthma specialist or rheumatologist; coverage duration 2 years; prerequisite Part D drug required for Fasenra; Exkivity no prerequisite Part D drug required.

    Exkivity

    Product-specific coverage when criteria met

    Exkivity: Member has documented locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutation AND has progressed on or after platinum-based chemotherapy AND prescriber is an oncologist.

    Coverage duration 2 years; no prerequisite Part D drug required.

    Fasenra

    Product-specific coverage when criteria met

    Fasenra: Either (1) severe asthma with eosinophilic phenotype despite current treatment with both inhaled corticosteroid AND an additional controller (LABA, leukotriene modifier, or sustained-release theophylline) OR (2) eosinophilic granulomatosis with polyangiitis (EGPA).

    Prescriber must be an asthma specialist (allergist, immunologist, pulmonologist) or a rheumatologist; coverage duration 2 years; prerequisite Part D drug required.

    Icatibant (HAE)

    Icatibant coverage requires verification and exclusions

    Icatibant: Documented diagnosis of hereditary angioedema (HAE) with history of at least one severe attack in the past 6 months AND for HAE Types 1 & 2 diagnosis confirmed by laboratory testing (e.g., low C4, reduced C1 esterase inhibitor level or function) AND prescriber is an allergist, hematologist, or immunologist.

    Icatibant will not be approved for acquired angioedema or concurrent ACE inhibitor use; coverage duration 2 years; no prerequisite Part D drug required.

    Genotropin - Pediatric GHD

    Genotropin pediatric criteria

    Genotropin - Pediatric GHD Initiation: Member has not attained epiphyseal closure by X-ray AND failed to respond to at least two standard GH stimulation tests AND documented gender-specific delayed bone age AND height >2 standard deviations below mean for age and sex AND presence of qualifying conditions (e.g., chronic renal insufficiency prior to transplantation, idiopathic short stature, Prader-Willi, Turner, SHOX deficiency).

    Prescriber restrictions and coverage duration 2 years; reauthorization requires documentation of improved growth rate per policy.

    Jakafi

    Jakafi coverage criteria

    Jakafi indications: Indications include chronic graft-versus-host disease (after failure of 1-2 systemic therapies) OR intermediate/high-risk myelofibrosis OR polycythemia vera with inadequate response/intolerance to hydroxyurea OR steroid-refractory acute GVHD.

    For myelofibrosis, subsequent authorization requires documentation of spleen size reduction or symptomatic improvement; coverage duration 2 years; prerequisite Part D drug required.

    Jaypirca — Indications and required information

    Coverage authorized when ALL of the following are documented:

    Jaypirca criteria: Member has documented diagnosis relevant to listed indications (chronic GVHD after failure of 1-2 systemic therapies; intermediate/high-risk myelofibrosis including primary, post-PV, post-ET; polycythemia vera with inadequate response/contraindication/intolerance to hydroxyurea; steroid-refractory acute GVHD).

    Coverage duration 2 years; subsequent authorizations for myelofibrosis require documentation of spleen size reduction or symptomatic improvement; prescriber must be hematologist/oncologist as applicable.

    Jubbonti — Indications and required information

    Coverage authorized when ANY of the following described indication pathways are met:

    Jubbonti pathways: 1) Relapsed or refractory mantle cell lymphoma (MCL) with ≥2 prior systemic therapies including a BTK inhibitor; OR 2) Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) previously treated with a covalent BTK inhibitor.

    Prescribed by or in consultation with an oncologist; coverage duration 2 years; prerequisite Part D drug required.

    Denosumab (Jubbonti entry) — Osteoporosis

    Coverage authorized when ANY of the following are met:

    Denosumab osteoporosis: 1) Member at high risk of fracture; OR 2) inadequate response or intolerance to at least one traditional osteoporosis treatment; OR 3) female on adjuvant aromatase inhibitor therapy to increase bone mass; OR 4) men on androgen deprivation for non-metastatic prostate cancer at high fracture risk; OR 5) glucocorticoid-induced osteoporosis at high fracture risk.

    Coverage duration 2 years; prerequisite Part D drug required.

    Jynarque (tolvaptan) — ADPKD initial and reauthorization

    Coverage authorized when specified monitoring and diagnosis requirements are met:

    Jynarque initial: Diagnosis of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD) AND monitoring plan: if on drug ≤18 months then ALT/AST/bilirubin measured baseline, 2 weeks, and 4 weeks after initiation, then monthly for first 18 months; if on drug >18 months then ALT/AST/bilirubin measured at least every 3 months AND no history of significant liver impairment (excluding uncomplicated polycystic liver disease).

    Coverage duration 1 year; reauthorization requires positive clinical response and continued monitoring.

    Jynarque reauth: Positive clinical response to therapy AND no signs/symptoms of hepatic injury or only uncomplicated polycystic liver disease AND ongoing liver enzyme monitoring per duration of therapy.

    Kalydeco — Cystic Fibrosis

    Coverage authorized when ALL of the following are met:

    Kalydeco criteria: Documented diagnosis of cystic fibrosis AND presence of at least one CFTR mutation responsive to Kalydeco based on clinical and/or in vitro data (or FDA-cleared mutation testing and sequencing if genotype unknown).

    Granules: age ≥1 month; exclusion if homozygous for F508del; coverage duration 2 years; no prerequisite Part D drug required.

    Kerendia — CKD or HF

    Coverage authorized when ALL of the following are met:

    Kerendia criteria: Documented diagnosis of chronic kidney disease associated with type 2 diabetes OR heart failure with left ventricular ejection fraction ≥40%.

    Coverage duration 2 years; no prerequisite Part D drug required.

    Kesimpta — Multiple Sclerosis

    Coverage authorized when ALL of the following are met:

    Kesimpta criteria: Documented diagnosis of relapsing forms of multiple sclerosis (including clinically isolated syndrome, relapsing-remitting, active secondary progressive).

    Prescriber must be a neurologist; coverage duration 2 years; no prerequisite Part D drug required.

    Kineret — RA and NOMID

    Coverage authorized when the indication-specific criteria are met:

    Kineret - RA: Diagnosis of moderately to severely active rheumatoid arthritis AND either trial/failure/contraindication/intolerance to two specified agents (Enbrel, one formulary adalimumab product, Orencia, Rinvoq, Xeljanz) OR attestation that trial is inappropriate OR continuation of prior therapy.

    Prescribed by or in consultation with a rheumatologist; reauthorization requires evidence of clinical response; coverage duration 1 year for RA reauth per chunk 61.

    Kineret - NOMID: Diagnosis of neonatal-onset multisystem inflammatory disease (NOMID) AND confirmation by NLRP3 gene mutation OR clinical criteria (two clinical symptoms from listed set) AND elevated acute phase reactants.

    Prescribed by/consult with allergist/immunologist, rheumatologist or pediatrician; reauth requires clinical response.

    Koselugo — Neurofibromatosis type 1

    Coverage authorized when ALL are met:

    Koselugo criteria: Documented diagnosis of neurofibromatosis type 1 (NF1) AND symptomatic, inoperable plexiform neurofibromas.

    Age ≥1 year; prescriber neurologist or oncologist; coverage duration 2 years; no prerequisite Part D drug required.

    Krazati — KRAS G12C cancers

    Coverage authorized when the indication-specific pathways are met:

    Krazati NSCLC: Locally advanced or metastatic NSCLC AND KRAS G12C mutation AND at least one prior systemic therapy.

    Prescriber oncologist; coverage duration 2 years; prerequisite Part D drug required.

    Krazati CRC: Locally advanced or metastatic colorectal cancer with KRAS G12C mutation AND prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy AND use in combination with cetuximab.

    Prescriber oncologist; coverage duration 2 years; prerequisite Part D drug required.

    Lapatinib — HER2-overexpressing breast cancer

    Coverage authorized when ALL are met:

    Lapatinib HER2+ advanced: Documented HER2-overexpressing advanced or metastatic breast cancer AND failed prior anthracycline and taxane AND failed prior trastuzumab AND concurrently treated with capecitabine.

    Prescriber must be an oncologist; coverage duration 2 years; prerequisite Part D drug required.

    Lapatinib HR+ metastatic: Hormone receptor positive metastatic breast cancer that overexpresses HER2 AND concurrently treated with letrozole.

    Prescriber must be an oncologist; coverage duration 2 years.

    Lazcluze — EGFR-mutant NSCLC

    Coverage authorized when ALL are met:

    Lazcluze criteria: Documented diagnosis of locally advanced or metastatic NSCLC used as first-line treatment in combination with amivantamab AND presence of EGFR exon19 deletion or exon21 L858R substitution mutations.

    Approve continuation of prior therapy; coverage duration 2 years; no prerequisite Part D drug required.

    Lenalidomide — multiple hematologic indications

    Coverage authorized when the indication-specific criteria are met:

    Lenalidomide indications: Indication-specific criteria for follicular lymphoma (previously treated, with rituximab), mantle cell lymphoma (relapsed/progressed after two prior therapies including bortezomib), marginal zone lymphoma (previously treated with rituximab), multiple myeloma (with dexamethasone or maintenance post-autologous HSCT), MDS with 5q-deletion transfusion-dependent anemia.

    Prescriber hematologist/oncologist; coverage duration 2 years; prerequisite Part D drug required.

    Lenvima — multiple oncology indications

    Coverage authorized when indication-specific criteria are met:

    Lenvima indications: Indications include advanced endometrial carcinoma (pMMR/non-MSI-H) in combination with pembrolizumab after prior therapy; advanced renal cell carcinoma with prior antiangiogenic therapy used with everolimus or first-line with pembrolizumab; unresectable hepatocellular carcinoma; locally recurrent/metastatic progressive radioactive iodine-refractory differentiated thyroid cancer.

    Prescriber must be an oncologist; coverage duration 2 years; prerequisite Part D drug required.

    Lidocaine patches — neuropathic pain

    Coverage authorized when ANY of the following are met:

    Lidocaine patch criteria: For postherpetic neuralgia or diabetic neuropathy: failure, adverse reaction, or contraindication to gabapentin OR member not a candidate for opioid or other oral pain management; new members may be approved if pain is currently well-controlled on lidocaine patches.

    Coverage duration 2 years; prerequisite Part D drug required.

    Livtencity — refractory CMV

    Coverage authorized when ALL are met:

    Livtencity criteria: Member weighing ≥35 kg AND documented post-transplant CMV infection/disease refractory to treatment with ganciclovir, valganciclovir, cidofovir, or foscarnet (with or without genotypic resistance).

    Coverage duration 2 years; prescriber specialty per product guidance; prerequisite Part D drug required.

    Lonsurf — metastatic colorectal and gastric cancers

    Coverage authorized when ALL are met:

    Lonsurf mCRC: Documented metastatic colorectal cancer AND prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy AND an anti-VEGF biologic AND if RAS wild-type, an anti-EGFR therapy.

    Prescriber must be an oncologist; coverage duration 2 years; prerequisite Part D drug required.

    Lonsurf gastric/GEJ: Metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy including a fluoropyrimidine, a platinum, and either a taxane or irinotecan, and if appropriate, HER2-targeted therapy.

    Prescriber oncologist; coverage duration 2 years; prerequisite Part D drug required.

    Lorbrena — ALK+ NSCLC

    Coverage authorized when ALL are met:

    Lorbrena criteria: Documented metastatic non-small cell lung cancer (NSCLC) with ALK-positive tumor.

    Prescribing physician must be an oncologist; coverage duration 2 years; no prerequisite Part D drug required.

    Lumakras — KRAS G12C NSCLC and CRC

    Coverage authorized when the indication-specific criteria are met:

    Lumakras indications: 1) KRAS G12C-mutated locally advanced or metastatic NSCLC after at least one prior systemic therapy; OR 2) KRAS G12C-mutated metastatic colorectal cancer used in combination with panitumumab after prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

    Prescriber oncologist; coverage duration 2 years; prerequisite Part D drug required.

    Lybalvi — schizophrenia and bipolar I

    Coverage authorized when ALL are met:

    Lybalvi criteria: Documented diagnosis of schizophrenia OR Bipolar I disorder.

    Prescribing physician must be a psychiatrist; coverage duration 2 years; no prerequisite Part D drug required.

    Lynparza — BRCA/HRR/HRD-based cancer indications

    Coverage authorized when the indication-specific genetic and treatment criteria are met:

    Lynparza - breast: Deleterious or suspected deleterious germline BRCA-mutated HER2-negative metastatic breast cancer treated with prior chemotherapy in neoadjuvant, adjuvant, or metastatic setting AND if hormone receptor-positive, prior endocrine therapy or contraindication to endocrine therapy; OR high-risk early breast cancer treated with neoadjuvant or adjuvant chemotherapy.

    Prescriber must be an oncologist; coverage duration 2 years; prerequisite Part D drug required.

    Lynparza - ovarian: Maintenance treatment of deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian/fallopian tube/primary peritoneal cancer in complete or partial response to first-line platinum-based chemotherapy; OR maintenance in combination with bevacizumab for HRD-positive disease in complete or partial response to first-line platinum-based chemotherapy; OR maintenance for recurrent disease in complete or partial response to platinum-based chemotherapy.

    Coverage duration 2 years; prescriber oncologist.

    Lynparza - pancreatic: Deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic adenocarcinoma with no disease progression after at least 16 weeks of first-line platinum-based chemotherapy.

    Lynparza — Indication-specific coverage criteria (summary)

    Covered when ALL of the following per indication are met:

    Lynparza indications (grouped): Member meets the specific indication criteria for one of Lynparza's approved indications (metastatic HER2-negative breast cancer with deleterious/suspected deleterious gBRCA mutation and prior chemotherapy; ovarian cancer maintenance per BRCA/HRD criteria; metastatic pancreatic adenocarcinoma with deleterious/suspected deleterious gBRCA mutation and no progression after ≥16 weeks of first-line platinum chemo; mCRPC with deleterious/suspected HRR gene mutation per specified prior therapy criteria).

    Prescriber must be an oncologist; coverage duration 2 years; prerequisite Part D drug required.

    Lytgobi — coverage criteria

    Covered when ALL of the following are met:

    Lytgobi initial therapy: Member has previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or rearrangements.

    Prescribed by or in consultation with an oncologist; coverage duration 2 years; no prerequisite Part D drug required.

    PAH / CTEPH agents — coverage criteria (grouped examples)

    Covered when ALL of the following are met:

    PAH/CTEPH drug group: Member has documented pulmonary arterial hypertension confirmed by right heart catheterization OR diagnosis of persistent/recurrent chronic thromboembolic pulmonary hypertension after surgical treatment or inoperable CTEPH.

    Prescriber must be a cardiologist or pulmonologist; coverage duration 2 years; no prerequisite Part D drug required for these products.

    Mekinist / Mektovi / other BRAF-targeted therapies — coverage criteria highlights

    Covered when ALL of the following are met:

    Mekinist single agent: Member has unresectable or metastatic melanoma with BRAF V600E or V600K mutation (other listed indications when combined with companion drugs per product labeling).

    Mekinist will not be approved as single agent for members who have received prior BRAF-inhibitor therapy; prescriber must be an oncologist; coverage duration 2 years.

    Orkambi — Initial Therapy

    Orkambi (example of explicit multi-component criteria)

    Orkambi initial criteria: Documented diagnosis of cystic fibrosis AND documentation that the member is homozygous for the F508del mutation.

    Coverage duration 2 years; no prerequisite Part D drug required.

    Pemazyre — Covered Indications

    Pemazyre — indication-specific criteria

    Pemazyre criteria: 1) Unresectable, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement AND previously treated; OR 2) Relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.

    Prescriber must be an oncologist; coverage duration 2 years; prerequisite Part D drug required as specified.

    Rinvoq — Multiple Indications

    Rinvoq — multiple disease-specific criteria (examples truncated)

    Rinvoq criteria examples: Indications include ankylosing spondylitis, atopic dermatitis (refractory moderate-to-severe with prior topical and systemic therapy trials), psoriatic arthritis, rheumatoid arthritis (requires trial of methotrexate/leflunomide/sulfasalazine and TNF inhibitor failure), ulcerative colitis, non-radiographic axial spondyloarthritis, and Crohn's disease (after TNF blocker failure unless clinically inadvisable).

    Prescriber must be a specialist; coverage duration 2 years; prerequisite Part D drug required for many indications.

    Rezdiffra — Initial and Reauthorization

    Rezdiffra — detailed NASH/MASH criteria

    Rezdiffra initial criteria: Diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) without cirrhosis AND fibrosis stage F2 or F3 confirmed by specified serum and imaging biomarkers OR liver biopsy within past 12 months AND presence of ≥1 metabolic risk factor (e.g., type 2 diabetes, hypertension, obesity).F2-F3

    Prescriber must be a gastroenterologist or hepatologist; reauthorization requires positive response and no progression to cirrhosis; coverage duration 2 years; no prerequisite Part D drug required.

    Rydapt (midostaurin) — Covered when ALL of the following are met

    Covered for specific hematologic indications with detailed requirements

    Rydapt AML first-line: Documented diagnosis of acute myeloid leukemia (AML) that is FLT3 mutation-positive AND Rydapt is being used as first-line therapy in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.

    Rydapt will not be approved as single-agent induction therapy for AML; prescriber must be hematologist/oncologist; coverage duration 2 years; no prerequisite Part D drug required.

    Rydapt other indications: Documented diagnosis of mast cell leukemia OR aggressive systemic mastocytosis (ASM) OR systemic mastocytosis with associated hematological neoplasm (SM-AHN).

    Prescriber hematologist/oncologist or allergist as indicated; coverage duration 2 years.

    Sapropterin Dihydrochloride — Hyperphenylalaninemia due to BH4-responsive PKU

    Coverage requires documented diagnosis

    Sapropterin Dihydrochloride - diagnosis: Member must have documented hyperphenylalaninemia (HPA) due to tetrahydrobiopterin (BH4)-responsive phenylketonuria (PKU).

    Prescribing physician must be a specialist in metabolic diseases or a geneticist; initial authorization 8 weeks then subsequent 2 years; continuing therapy requires demonstrated improvement.

    Biologics for dermatologic, rheumatologic, and GI indications (examples: Skyrizi, Stelara)

    Coverage requires diagnosis and prior treatment trials or specialty prescriber

    Skyrizi - Plaque Psoriasis: Documented moderate-to-severe plaque psoriasis AND failure or intolerance to specified topical/systemic therapies as listed.

    Prescribed by or in consultation with dermatologist, rheumatologist, or gastroenterologist; coverage duration 2 years; prerequisite Part D drug required.

    Stelara - All indications: Documented diagnosis per indication (Crohn's, plaque psoriasis, psoriatic arthritis, ulcerative colitis) AND trial, intolerance, or contraindication to Yesintek or Steqeyma where specified.

    Prescribed by or in consultation with relevant specialist; coverage duration 2 years.

    Transmucosal Immediate-Release Fentanyl (TIRF) — Covered when ALL of the following are met

    Restricted to adult cancer patients with breakthrough pain who are opioid tolerant

    TIRF indication: Management of breakthrough pain in adult cancer patients who are already receiving and tolerant to around-the-clock opioid therapy for underlying persistent cancer pain (fentanyl lozenges approvable for patients 16 years and older).

    Patients must meet opioid tolerance definition; TIRF products not covered for any non-cancer pain indication; prescriber oncologist or pain management specialist; coverage duration 2 years.

    Opioid tolerance: Patient meets opioid tolerance criteria (taking around-the-clock opioids such as morphine oral 60 mg daily or more, fentanyl transdermal 25 mcg/hour or more, oxycodone oral 30 mg daily or more, hydromorphone oral 8 mg daily or more, or equianalgesic dose of another opioid daily for a week or longer).

    Patient must remain on around-the-clock opioids when taking fentanyl transmucosal.

    Tibsovo (ivosidenib) — IDH1-mutated hematologic and solid tumor indications

    Covered for specified indications with mutation documentation and treatment context

    Tibsovo indications: Relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation OR newly diagnosed AML with a susceptible IDH1 mutation used as monotherapy or with azacitidine in patients ≥75 years or with comorbidities precluding intensive induction chemotherapy OR locally advanced/metastatic cholangiocarcinoma previously treated.

    Prescriber must document IDH1 mutation status and treatment intent; prescriber hematologist/oncologist; coverage duration 2 years.

    Cystic Fibrosis (Truqap) — Initial

    Covered when ALL of the following are met

    Truqap (CF) initial: Documented diagnosis of cystic fibrosis AND at least one CFTR gene mutation that is F508del OR a CFTR mutation responsive based on clinical and/or in vitro data; age/formulation limits apply (granule packets 2 to <6 years; tablets ≥6 years); prescribed by or in consultation with a pulmonologist or CF specialist.

    Coverage duration 2 years; no prerequisite Part D drug required.

    Locally Advanced/Metastatic HR-positive, HER2-negative Breast Cancer (Tukysa)

    Covered when ALL of the following are met

    Tukysa (breast cancer): Documented diagnosis of locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer AND documented PIK3CA/AKT1/PTEN alteration AND disease progression on at least one endocrine-based regimen in the metastatic setting OR recurrence on or within 12 months of adjuvant therapy AND to be used in combination with fulvestrant.

    Coverage duration 2 years; prerequisite Part D drug required; prescriber must be an oncologist per product guidance.

    Rheumatologic and Related Indications (selected biologic/small molecules)

    Covered when ALL of the following are met (indication-specific)

    RA initial: Moderately to severely active rheumatoid arthritis AND either (a) trial and failure, contraindication, or intolerance to two of the following: etanercept, one formulary adalimumab product, abatacept, upadacitinib, tofacitinib OR attestation that trial is inappropriate; OR (b) continuation of prior therapy.

    Prescribed by or in consultation with a rheumatologist; reauthorization requires demonstration of positive clinical response; prerequisite Part D drug required varies by product.

    SJIA initial: Active systemic juvenile idiopathic arthritis AND trial and failure/contraindication/intolerance to conventional therapies at maximally tolerated doses (minimum 1 month NSAID, 3 months methotrexate, 2 weeks systemic glucocorticoid) OR attestation that trials are inappropriate.

    Prescribed by a rheumatologist; reauth requires clinical response.

    SSc-ILD initial: Diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD) documented by exclusion of other causes AND HRCT pattern consistent with SSc-ILD or surgical lung biopsy/HRCT concordant with SSc-ILD.

    Voquezna (H. pylori, erosive esophagitis, maintenance)

    Covered when ALL of the following are met (indication-specific)

    Voquezna - H. pylori: Diagnosis of H. pylori infection AND trial and failure, contraindication, or intolerance to bismuth quadruple therapy; or used in combination regimens per labeling.

    Coverage duration H. pylori: 1 month; prerequisite Part D drug required.

    Voquezna - HRH/MHRH: Erosive esophagitis: trial and inadequate response/contraindication/intolerance to two generic PPIs for healing; maintenance similarly requires prior inadequate response to two generic PPIs.

    Coverage durations per indication (HRH 2 months; MHRH 6 months); prerequisite Part D drug required.

    Antiviral/Antifungal and Hepatology Agents (selected)

    Covered when applied consistent with indication-specific guidance

    Voriconazole: Documented diagnosis of specified serious fungal infections (e.g., invasive aspergillosis, candidemia, CNS infection, endocarditis, invasive pulmonary aspergillosis, Scedosporium/Fusarium refractory or intolerant to other therapy).

    Coverage duration 2 years; no prerequisite Part D drug required.

    Vosevi: Use applied consistent with current AASLD-IDSA guidance; prescriber must be gastroenterologist, hepatologist, or infectious disease specialist; coverage per guidance.

    No prerequisite Part D drug required.

    Vowst (recurrent C. difficile infection)

    Covered when ALL of the following are met

    Vowst: Diagnosis of recurrent Clostridioides difficile infection AND patient completed oral vancomycin or fidaxomicin 2-4 days prior to initiating Vowst.

    Prescribed by or in consultation with gastroenterologist or infectious disease specialist; coverage duration 14 days; prerequisite Part D drug required.

    Vyndamax (ATTR-CM)

    Covered when ALL of the following are met

    Vyndamax initial/reauth: Diagnosis of transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) AND one of: presence of a TTR mutation, biopsy demonstrating TTR amyloid deposits, OR cardiac MRI/scintigraphy suggestive of amyloidosis plus absence of light-chain amyloidosis; documentation of NYHA Functional Class I-III heart failure.

    Prescribed by a cardiologist; coverage duration plan year; reauth requires continued NYHA I-III status; no prerequisite Part D drug required.

    Wyost (denosumab) — bone related oncology indications

    Covered when ANY of the following are met

    Wyost coverage: Indications include prevention of skeletal-related events in multiple myeloma or bone metastases from solid tumors; treatment of unresectable giant cell tumor of bone when surgery would likely cause severe morbidity; treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.

    Coverage duration 2 years; prerequisite Part D drug required.

    Wyost (example detailed criteria)

    Covered when ALL of the following are met for Wyost (denosumab):

    Wyost authorization: Member has a documented diagnosis of one of: (1) von Hippel-Lindau disease requiring therapy for associated RCC, CNS hemangioblastomas, or pancreatic NETs not requiring immediate surgery; OR (2) advanced RCC following PD-1/PD-L1 inhibitor and a VEGF-TKI; OR (3) locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL).

    Prescriber must be an oncologist; coverage duration 2 years; prerequisite Part D drug required.

    Wyost (denosumab) - prevention and other indications

    Covered when ANY of the following indications are met:

    Wyost other indications: Prevention of skeletal-related events in multiple myeloma or bone metastases from solid tumors; unresectable giant cell tumor of bone where surgical resection likely causes severe morbidity; hypercalcemia of malignancy refractory to bisphosphonate therapy.

    Coverage duration 2 years; prerequisite Part D drug required.

    Xalkori (crizotinib) criteria

    Covered when ALL of the following are met:

    Xalkori authorization: Member has metastatic NSCLC that is ALK-positive OR documented ROS1-positive tumors OR relapsed/refractory systemic ALCL that is ALK-positive OR unresectable/recurrent/refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive.

    Prescribing physician must be an oncologist; coverage duration 2 years; no prerequisite Part D drug required.

    Xdemvy (lotilaner) criteria

    Covered when the following are met:

    Xdemvy authorization: Member has a documented diagnosis of Demodex blepharitis.

    Must be prescribed by or in consultation with an ophthalmologist or optometrist; coverage duration 2 years; no prerequisite Part D drug required.

    Benlysta (belimumab) exclusions: Benlysta will not be approved as monotherapy, for members with severe active lupus nephritis or severe active central nervous system (CNS) lupus, for members who are autoantibody negative (e.g., negative ANA, anti-dsDNA, anti‑Sm), or in combination with other biologics or intravenous cyclophosphamide. Required medical information includes documentation of active, autoantibody‑positive systemic lupus erythematosus (SLE) or active lupus nephritis and concurrent use of standard therapy (for example antimalarials, corticosteroids, or immunosuppressives).

    Armodafinil and modafinil will be considered only for patients with a documented diagnosis of narcolepsy, excessive sleepiness associated with obstructive sleep apnea, or shift‑work sleep disorder. Coverage will not be approved for generalized fatigue, jet lag, or sleep deprivation not associated with a covered diagnosis. Prior authorization does not require use of a prerequisite Part D drug and standard coverage duration is 2 years.

    Braftovi is approved only for tumors with an appropriate BRAF V600E mutation context per indication; it is not indicated for treatment of patients with wild‑type BRAF melanoma or wild‑type BRAF colorectal cancer (CRC). Prescriber must be an oncologist and required mutation documentation is part of the medical record.

    Cotellic is indicated for unresectable or metastatic melanoma with a BRAF V600E or V600K mutation (when used with vemurafenib) or for certain histiocytic neoplasms as monotherapy. It is not indicated for patients with wild‑type BRAF melanoma. Prescriber must be an oncologist and standard coverage duration is 2 years.

    Dupixent is authorized for labeled chronic indications (e.g., atopic dermatitis, eosinophilic asthma, CRSwNP, prurigo nodularis, eosinophilic esophagitis) with required prior topical or systemic therapy trials per indication. Importantly, Dupixent will not be approved for the relief of acute bronchospasm or status asthmaticus. Prescribing specialist involvement is expected and coverage duration is typically 2 years.

    Icatibant is authorized for Hereditary Angioedema (HAE) when laboratory confirmation and clinical history support the diagnosis (e.g., history of at least one severe attack in prior 6 months and low C4 or reduced C1 esterase inhibitor level/function for Types 1 & 2). Icatibant will not be approved for members with acquired angioedema or for members taking an ACE inhibitor concurrently. Prescriber should be an allergist, hematologist, or immunologist.

    Iclusig (ponatinib) coverage requires indication‑specific documentation (for example T315I mutation status or disease phase). The policy specifies that Iclusig will not be approved for members with newly diagnosed chronic‑phase CML; prescriber must be a hematologist or oncologist and a prerequisite Part D drug may be required for some uses.

    Kalydeco (ivacaftor) coverage is genotype‑dependent. Authorization requires documentation of cystic fibrosis and at least one CFTR mutation that is responsive to Kalydeco based on clinical and/or in vitro data or FDA‑cleared testing. The policy explicitly notes an exclusion: Kalydeco is not effective in patients homozygous for the F508del CFTR mutation, and coverage would be denied for that genotype. Granule formulation age limits and prescriber specialty requirements apply.

    For Mekinist (trametinib) the policy includes specific prior‑therapy exclusions: when used as a single agent it is indicated for BRAF‑mutant disease, but Mekinist will not be approved as a single agent for members who have received prior BRAF‑inhibitor therapy. Prescriber must be an oncologist and required mutation documentation is part of the required medical information.

    Quinine sulfate is not covered for the treatment or prevention of nocturnal leg cramps. The policy states explicitly that coverage will not be approved for nocturnal leg cramps; approvals are applied only where medically accepted indications exist.

    Transmucosal Immediate‑Release Fentanyl (TIRF) products are restricted to management of breakthrough pain in adult cancer patients who are already tolerant to around‑the‑clock opioid therapy. The policy states that TIRF products will not be covered for any non‑cancer pain indication. Documentation must show opioid tolerance per the opioid‑tolerant definition; prescriber is typically an oncologist or pain specialist.

    Tadalafil is excluded from coverage when requested for the treatment of erectile dysfunction. Its covered use in the formulary context is for BPH and other medically‑accepted indications with required prior therapy documentation; for ED the policy explicitly states Tadalafil is excluded from coverage for erectile dysfunction.

    Tafinlar (dabrafenib) is approved for BRAF‑mutant indications per label but is not indicated for patients with wild‑type BRAF mutations. The policy requires mutation documentation and oncologist involvement for covered BRAF‑mutant indications.

    The formulary shows many product entries where the Exclusion Criteria field is N/A or blank; in other words, for numerous listed drugs there are no explicit exclusions provided in this excerpt. Reviewers and providers should assume coverage is guided by the listed indication‑specific criteria unless an explicit exclusion is shown.

    Zelboraf (vemurafenib) is indicated only for patients with a qualifying BRAF V600 mutation; it is not indicated for treatment of patients with wild‑type BRAF melanoma. Prescriber must be an oncologist or hematologist and required mutation testing must be documented.

    Summary — Benlysta exclusions and NMN context: Benlysta will not be approved as monotherapy, for members with severe active lupus nephritis or severe active CNS lupus, for autoantibody‑negative members, or in combination with other biologics or intravenous cyclophosphamide. The required medical information includes documentation of active, autoantibody‑positive SLE and concurrent standard therapy; these exclusion conditions underpin any denial or 'not medically necessary' determination for Benlysta.

    The excerpt does not include standalone 'Not Medically Necessary' (NMN) declarations beyond the exclusion language embedded for specific products; multiple chunks in this segment show either 'All Medically‑accepted Indications' or list exclusions. Therefore, the document portion provided contains no general NMN statements separate from the product‑level exclusion language.

    Within the available excerpt there are no additional explicit NMN statements for other products beyond those exclusion conditions shown in product entries. Where an entry lists exclusions (for example Benlysta, Iclusig, Mekinist, Quinine, Tadalafil, TIRF products), those function as the policy's NMN/denial‑risk provisions in this segment.

    Rubraca (rucaparib) maintenance therapy for recurrent ovarian cancer requires documentation of a deleterious BRCA mutation and response to platinum‑based chemotherapy; the policy states Rubraca will not be approved for concurrent use with other chemotherapy agents. Prescriber must be an oncologist and the exclusion for concurrent chemotherapy use is an explicit coverage restriction.

    Rydapt (midostaurin) is authorized in specific hematologic indications but the policy explicitly states that Rydapt will not be approved as single‑agent induction therapy for the treatment of patients with AML. For first‑line FLT3‑positive AML use it must be given in combination with standard cytarabine/daunorubicin induction and cytarabine consolidation; prescriber must be a hematologist/oncologist.

    Across the excerpted product list many entries do not include explicit 'Not Medically Necessary' conditions; where coverage is denied or not approved the policy uses product‑level exclusion language. Users should consult each product's entry for specific exclusions, as a general NMN list is not present in these chunks.

    Prior Authorization, Documentation, and Prescriber Requirements

    Prior Authorization

    Abilify Mycite prior authorization

    Prior authorization required: member must have documented diagnosis of bipolar I disorder, major depressive disorder, or schizophrenia; documentation of worsening symptoms with oral aripiprazole; prescriber must be a psychiatrist; coverage duration 2 years; prerequisite Part D drug required.

    • Document diagnosis of bipolar I disorder, major depressive disorder, or schizophrenia
    • Document worsening symptoms with oral aripiprazole
    • Prescriber must be a psychiatrist
    • Coverage duration: 2 years
    • Prerequisite Part D drug required
    Prior Authorization

    Adalimumab products prior authorization

    Prior authorization required with documented diagnosis appropriate to the indication and prescriber specialty/consultation (e.g., dermatologist, gastroenterologist, ophthalmologist, or rheumatologist); coverage duration 2 years; prerequisite Part D drug may be required as specified per indication.

    • Document indication-specific diagnosis (e.g., Crohn's disease, plaque psoriasis, RA)
    • Prescribed by or in consultation with appropriate specialist
    • Coverage duration: 2 years
    • Prerequisite Part D drug requirement varies by product
    Prior Authorization

    Armodafinil/Modafinil prior authorization

    Prior authorization requires documented diagnosis of narcolepsy, excessive sleepiness associated with obstructive sleep apnea, or shift‑work sleep disorder; exclusions: generalized fatigue, jet lag, or sleep‑deprivation not associated with a covered diagnosis; coverage duration 2 years.

    • Document diagnosis of narcolepsy, OSA-associated hypersomnolence, or shift‑work sleep disorder
    • Note exclusion: generalized fatigue, jet lag, non‑covered sleep deprivation
    • Coverage duration: 2 years
    Prior Authorization

    Prior authorization requirement (general)

    Prior authorization is required for listed specialty drugs and generally requires a documented diagnosis and product‑specific required medical information; coverage durations are commonly set (typically 2 years).

    • Submit documented diagnosis matching product indication
    • Include all product‑specific required medical information per policy
    • Expect typical coverage duration of 2 years
    Prior Authorization

    Empaveli prior auth specifics

    Initial PA requires documented diagnosis of paroxysmal nocturnal hemoglobinuria (PNH); reauthorization requires demonstration of a positive clinical response to therapy; prescriber for initial PNH should be a hematologist/oncologist or nephrologist.

    • Document diagnosis of PNH for initial approval
    • For reauth, document clinical response to therapy
    • Initial prescriber: hematology/oncology or nephrology
    Prior Authorization

    Exkivity - prior authorization

    Prior authorization requires documented diagnosis of locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutation and progression on or after platinum‑based chemotherapy; prescriber must be an oncologist; coverage duration 2 years.

    • Document EGFR exon 20 insertion mutation and disease status (locally advanced/metastatic)
    • Document progression on or after platinum‑based chemotherapy
    • Prescriber must be an oncologist
    • Coverage duration: 2 years
    Prior Authorization

    Fasenra - prior authorization

    Authorization requires documented severe eosinophilic asthma despite inhaled corticosteroid plus an additional controller OR eosinophilic granulomatosis with polyangiitis (EGPA); prescriber must be an asthma specialist or rheumatologist; criteria requires use of a prerequisite Part D drug; coverage duration 2 years.

    • Document severe eosinophilic asthma despite inhaled corticosteroid + controller, or diagnosis of EGPA
    • Prescriber: asthma specialist (allergist, immunologist, pulmonologist) or rheumatologist
    • Criteria requires use of a prerequisite Part D drug
    • Coverage duration: 2 years
    Prior Authorization

    Increlex - prior authorization

    Authorization requires documented severe primary IGF‑1 deficiency: height SDS ≤ -3.0, basal IGF‑1 SDS ≤ -3.0, normal/elevated GH or GH gene deletion, and radiographs documenting open epiphyses if Tanner stage III or greater; prescriber must be an endocrinologist; coverage duration 2 years.

    • Document severe primary IGF‑1 deficiency (height and IGF‑1 SDS criteria)
    • Provide GH level or GH gene deletion and radiographs for epiphyseal status if Tanner stage ≥III
    • Prescriber must be an endocrinologist
    • Coverage duration: 2 years
    Prior Authorization

    Jaypirca — PA required

    Prior authorization required with documentation of the indicated diagnosis and prior systemic therapy failures for chronic GVHD, myelofibrosis, polycythemia vera, or steroid‑refractory acute GVHD; coverage duration 2 years; subsequent authorization for myelofibrosis requires documentation of spleen size reduction or symptomatic improvement.

    • Document diagnosis and prior lines of systemic therapy (as applicable)
    • For myelofibrosis, provide evidence of spleen reduction or symptomatic improvement for reauth
    • Prescriber specialty as indicated
    • Coverage duration: 2 years
    Prior Authorization

    Jubbonti — PA and prescriber restriction

    Prior authorization requires documentation showing relapsed/refractory mantle cell lymphoma with ≥2 prior systemic therapies including a BTK inhibitor, or CLL/SLL previously treated with a covalent BTK inhibitor; prescriber must be an oncologist; coverage duration 2 years.

    • Document relapsed/refractory MCL with ≥2 prior systemic therapies including a BTK inhibitor OR CLL/SLL previously treated with a covalent BTK inhibitor
    • Prescriber: oncologist or consult with one
    • Coverage duration: 2 years
    Documentation Required

    Jynarque — monitoring requirements

    Initial authorization requires diagnosis of rapidly progressing ADPKD and specified liver enzyme monitoring: if ≤18 months on drug measure ALT/AST/bilirubin at baseline, 2 and 4 weeks, then monthly for first 18 months; if >18 months, measure at least every 3 months; reauthorization requires clinical response; coverage duration 1 year.

    • Document diagnosis of rapidly progressing ADPKD
    • Provide liver enzyme monitoring per schedule (baseline, 2w, 4w, then monthly for first 18 months; then at least every 3 months)
    • Confirm no history of significant liver impairment (excluding uncomplicated polycystic liver disease)
    • Coverage duration: 1 year
    Prior Authorization

    Kalydeco — genotype-based PA

    Prior authorization requires documented diagnosis of cystic fibrosis and presence of at least one CFTR mutation responsive to Kalydeco (or FDA‑cleared mutation testing if genotype unknown); granules age ≥1 month; exclusion if homozygous for F508del; coverage duration 2 years.

    • Document CF diagnosis and at least one CFTR mutation responsive to Kalydeco or provide FDA‑cleared mutation testing if genotype unknown
    • Granules: patient ≥1 month of age
    • Do not approve if homozygous for F508del mutation
    • Coverage duration: 2 years
    Documentation Required

    Kerendia — indication documentation

    Prior authorization requires documentation of chronic kidney disease associated with type 2 diabetes OR heart failure with LVEF ≥40%; coverage duration 2 years.

    • Document CKD associated with type 2 diabetes or HF with LVEF ≥40%
    • Coverage duration: 2 years
    Prior Authorization

    Kesimpta — MS prescriber requirement

    Kesimpta requires documented diagnosis of relapsing forms of multiple sclerosis; prescribing physician must be a neurologist; coverage duration 2 years.

    • Document relapsing form of MS (CIS, relapsing‑remitting, active secondary progressive)
    • Prescriber must be a neurologist
    • Coverage duration: 2 years
    Prior Authorization

    Kineret — RA and NOMID criteria

    Kineret PA for RA initial therapy requires trial/failure/contraindication/intolerance to two specified agents (or attestation that trials are inappropriate) or continuation of prior therapy; NOMID requires genetic confirmation OR clinical criteria plus elevated acute phase reactants; prescriber specialty and reauthorization requirements vary; criteria requires use of a prerequisite Part D drug.

    • For RA: document diagnosis and trial/failure/contraindication/intolerance to two listed agents OR attestation OR continuation of prior therapy
    • For NOMID: provide NLRP3 mutation or clinical criteria (two listed symptoms) plus elevated acute phase reactants
    • Prescriber: rheumatologist (RA) or allergist/immunologist/pediatrician (NOMID)
    • Reauth requires demonstration of positive clinical response
    Prior Authorization

    Koselugo — NF1 criteria

    Koselugo PA requires documented diagnosis of neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas; patient age ≥1 year; prescriber must be a neurologist or oncologist; coverage duration 2 years.

    • Document NF1 diagnosis and symptomatic, inoperable plexiform neurofibromas
    • Patient age ≥1 year
    • Prescriber: neurologist or oncologist
    • Coverage duration: 2 years
    Prior Authorization

    Krazati — KRAS G12C criteria

    Krazati PA for NSCLC requires KRAS G12C mutation and at least one prior systemic therapy; for CRC requires KRAS G12C mutation, prior fluoropyrimidine/oxaliplatin/irinotecan chemotherapy and use in combination with cetuximab; prescriber must be an oncologist; coverage duration 2 years.

    • For NSCLC: document KRAS G12C mutation and prior systemic therapy
    • For CRC: document KRAS G12C mutation, prior fluoropyrimidine/oxaliplatin/irinotecan chemotherapy, and planned combination with cetuximab
    • Prescriber: oncologist
    • Coverage duration: 2 years
    Prior Authorization

    Lapatinib — refractory HER2+ criteria

    Lapatinib PA for HER2‑overexpressing advanced/metastatic breast cancer requires documented HER2 overexpression, failure of anthracycline and taxane and prior trastuzumab, and concurrent treatment with capecitabine; prescriber must be an oncologist; coverage duration 2 years.

    • Document HER2‑overexpressing advanced/metastatic breast cancer
    • Document prior failures of anthracycline, taxane, and trastuzumab
    • Document concurrent capecitabine use
    • Prescriber: oncologist
    • Coverage duration: 2 years
    Prior Authorization

    Lazcluze — EGFR mutation and combo use

    Lazcluze PA as first‑line NSCLC in combination with amivantamab requires EGFR exon 19 deletion or exon 21 L858R substitution mutation and use for locally advanced or metastatic disease; coverage duration 2 years; continuation of prior therapy approvable where applicable.

    • Document NSCLC locally advanced or metastatic
    • Document EGFR exon 19 deletion or exon 21 L858R mutation
    • Document intended combination with amivantamab as first‑line therapy
    • Coverage duration: 2 years
    Prior Authorization

    Lenalidomide — hematologic oncology criteria

    Lenalidomide PA lists multiple hematologic oncology indications (FL, MCL, MZL, MM, MDS with 5q deletion) with required diagnosis‑specific regimen or combination details; prescriber must be a hematologist/oncologist; criteria requires use of a prerequisite Part D drug; coverage duration 2 years.

    • Document precise hematologic diagnosis and intended combination/regimen per indication
    • Prescriber must be a hematologist/oncologist
    • Criteria requires use of a prerequisite Part D drug
    • Coverage duration: 2 years
    Prior Authorization

    Lenvima — multiple oncology indications

    Lenvima PA includes multiple oncology indications (advanced endometrial carcinoma pMMR/non‑MSI‑H with pembrolizumab after prior therapy; advanced RCC with specified prior antiangiogenic therapy or first‑line with pembrolizumab; unresectable HCC; radioactive iodine‑refractory thyroid cancer); prescriber must be an oncologist; criteria requires use of a prerequisite Part D drug.

    • Document indication‑specific diagnosis and prior therapy per the listed pathways
    • Prescriber must be an oncologist
    • Criteria requires use of a prerequisite Part D drug
    • Coverage duration: 2 years
    Step Therapy

    Lidocaine patches — neuropathic pain prerequisite

    Lidocaine patches require prior failure, adverse reaction, or contraindication to gabapentin for postherpetic neuralgia or diabetic neuropathy; can be approved for new members already well controlled on patches; coverage duration 2 years.

    • Document prior failure/adverse reaction/contraindication to gabapentin for PHN or diabetic neuropathy
    • If new member, document current pain control on lidocaine patches
    • Coverage duration: 2 years
    Prior Authorization

    Livtencity — refractory CMV criteria

    Livtencity requires PA demonstrating member ≥35 kg with documented post‑transplant CMV infection/disease refractory to ganciclovir, valganciclovir, cidofovir, or foscarnet (with or without genotypic resistance); coverage duration 2 years.

    • Document weight ≥35 kg
    • Document refractory post‑transplant CMV infection/disease after listed antivirals (± genotypic resistance)
    • Coverage duration: 2 years
    Prior Authorization

    Lonsurf — refractory GI cancer criteria

    Lonsurf requires documented metastatic colorectal cancer or metastatic gastric/GEJ adenocarcinoma and prior lines of therapy as specified (fluoropyrimidine-, oxaliplatin-, and irinotecan‑based chemotherapy, anti‑VEGF biologic, and if RAS wild‑type an anti‑EGFR therapy for mCRC; specified prior chemo lines for gastric/GEJ); prescriber must be an oncologist; coverage duration 2 years.

    • Document prior chemotherapy history consistent with indication (fluoropyrimidine, oxaliplatin, irinotecan; anti‑VEGF; anti‑EGFR if RAS wild‑type)
    • Prescriber: oncologist
    • Coverage duration: 2 years
    Prior Authorization

    Lorbrena — ALK+ NSCLC

    Lorbrena requires documented metastatic NSCLC with ALK‑positive tumor; prescriber must be an oncologist; coverage duration 2 years.

    • Document metastatic NSCLC with ALK‑positive tumor
    • Prescriber must be an oncologist
    • Coverage duration: 2 years
    Prior Authorization

    Lumakras — KRAS G12C NSCLC/CRC

    Lumakras requires KRAS G12C‑mutated locally advanced/metastatic NSCLC after at least one prior systemic therapy, or KRAS G12C‑mutated metastatic CRC in combination with panitumumab after prior fluoropyrimidine, oxaliplatin, and irinotecan‑based chemotherapy; prescriber must be an oncologist; criteria requires use of a prerequisite Part D drug.

    • Document KRAS G12C mutation and prior systemic therapy (NSCLC) or combination with panitumumab after listed prior chemo (CRC)
    • Prescriber: oncologist
    • Criteria requires use of a prerequisite Part D drug
    • Coverage duration: 2 years
    Prior Authorization

    Lybalvi — psychiatric prescriber restriction

    Lybalvi requires documented diagnosis of schizophrenia or Bipolar I disorder; prescriber must be a psychiatrist; coverage duration 2 years.

    • Document diagnosis of schizophrenia or Bipolar I disorder
    • Prescriber must be a psychiatrist
    • Coverage duration: 2 years
    Prior Authorization

    Lynparza — BRCA/HRR-based indications

    Lynparza requires documentation of deleterious or suspected deleterious BRCA or HRR/HRD status and prior lines of therapy as specified by indication (breast, ovarian, pancreatic, prostate); prescriber must be an oncologist; prior authorization required; coverage duration 2 years; criteria requires use of a prerequisite Part D drug.

    • Provide germline or somatic BRCA/HRR/HRD mutation documentation per indication
    • Document prior therapy history as specified for the cancer type
    • Prescriber must be an oncologist
    • Prior authorization required; coverage duration 2 years
    • Prerequisite Part D drug required
    Prior Authorization

    Lynparza prior authorization

    Prior authorization required with documentation of specific mutation status and prior therapy history for Lynparza; prescriber must be an oncologist; coverage duration 2 years.

    • Submit mutation testing results (germline or somatic BRCA/HRR)
    • Document prior chemotherapy/endocrine therapy as required by indication
    • Prescriber: oncologist
    • Coverage duration: 2 years
    Prior Authorization

    Lytgobi prior authorization

    Prior authorization required for Lytgobi with documentation of previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or rearrangements; prescriber involvement by an oncologist required; coverage duration 2 years.

    • Document FGFR2 gene fusion or rearrangement in intrahepatic cholangiocarcinoma
    • Document prior treatment history
    • Prescriber: oncologist or consultation with one
    • Coverage duration: 2 years
    Prior Authorization

    PAH and CTEPH drug prior authorization

    PAH and CTEPH drugs require documented diagnosis confirmed by right heart catheterization for PAH or documented persistent/recurrent CTEPH after surgical treatment or inoperable status; prescriber must be a cardiologist or pulmonologist; coverage duration 2 years.

    • For PAH: provide right heart catheterization confirmation
    • For CTEPH: document persistent/recurrent disease after surgery or inoperable status
    • Prescriber: cardiologist or pulmonologist
    • Coverage duration: 2 years
    Prior Authorization

    Orkambi PA

    Prior authorization requires documentation of cystic fibrosis and homozygous F508del mutation for Orkambi; coverage duration 2 years.

    • Document CF diagnosis and homozygous F508del mutation
    • Coverage duration: 2 years
    Prior Authorization

    Otezla PA

    Prior authorization for Otezla requires documented diagnosis appropriate to the indication (PsA, plaque psoriasis, Behcet's) and prior topical/systemic treatment failures as specified; prescriber should be or consult a dermatologist or rheumatologist; coverage duration 2 years.

    • Document diagnosis per indication and prior topical/systemic therapy failures where specified
    • Prescriber: dermatologist or rheumatologist (or consult)
    • Coverage duration: 2 years
    Prior Authorization

    Praluent/Repatha class PA

    Praluent and similar PCSK9 inhibitors require PA documenting elevated LDL‑C despite high‑intensity statin therapy or statin intolerance and a diagnosis consistent with atherosclerotic cardiovascular disease or familial hypercholesterolemia; prerequisite Part D drug required.

    • Document elevated LDL‑C despite high‑intensity statin or statin intolerance
    • Provide diagnosis: ASCVD, HeFH, or HoFH per criteria
    • Prerequisite Part D drug required
    Prior Authorization

    Rydapt (midostaurin) — AML and mast cell disease

    Rydapt requires prior authorization when used as first‑line therapy in FLT3 mutation‑positive AML in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation; Rydapt will not be approved as single‑agent induction therapy for AML.

    • Document FLT3 mutation‑positive AML and planned combination with standard induction and consolidation regimens
    • Note: Rydapt will not be approved as single‑agent induction therapy for AML
    Prior Authorization

    Transmucosal Fentanyl (TIRF) prior auth conditions

    TIRF products require documentation that the patient is an adult cancer patient already tolerant to around‑the‑clock opioid therapy for persistent cancer pain; pediatric approval for fentanyl lozenges limited to patients ≥16 years; TIRF products will not be covered for any non‑cancer pain indication.

    • Document adult cancer diagnosis and opioid tolerance to around‑the‑clock opioids
    • If fentanyl lozenges requested for pediatric patients, age ≥16 required
    • TIRF products not covered for non‑cancer pain
    Prior Authorization

    Truqap — Prior authorization

    Prior authorization for Truqap requires documentation of CF diagnosis, qualifying CFTR mutation, age/formulation limits, and specialist prescriber; coverage duration 2 years.

    • Document CF diagnosis and qualifying CFTR mutation
    • Provide age/formulation information (granules vs tablets as applicable)
    • Prescriber: pulmonologist or CF care specialist
    • Coverage duration: 2 years
    Prior Authorization

    Tukysa — Prior authorization

    Tukysa prior authorization requires documented locally advanced or metastatic HR‑positive, HER2‑negative breast cancer with documented PIK3CA/AKT1/PTEN alteration, prior endocrine therapy criteria, and is to be used in combination with fulvestrant; criteria requires use of a prerequisite Part D drug; coverage duration 2 years.

    • Document HR‑positive, HER2‑negative locally advanced/metastatic breast cancer
    • Document PIK3CA/AKT1/PTEN alteration
    • Document progression on or after at least one endocrine‑based regimen or recurrence within 12 months of adjuvant therapy
    • Intended combination with fulvestrant
    • Prerequisite Part D drug required
    • Coverage duration: 2 years
    Prior Authorization

    Ubrelvy and similar products — Prior authorization

    Prior authorization required for Ubrelvy and similar products with documentation of inadequate response/intolerance/contraindication to required comparators; some indications require prior Part D drug therapy; coverage durations commonly 2 years.

    • Document inadequate response/intolerance/contraindication to required comparators per indication
    • Note whether prior Part D drug therapy is required for the specific indication
    • Coverage duration commonly 2 years
    Prior Authorization

    Prior authorization and prescriber restrictions

    Prior authorization is required for listed specialty drugs; certain drugs have prescriber restrictions (e.g., oncologist required for specific oncology agents); providers must follow product‑specific prescriber requirements.

    • Check product entry for prescriber restriction (e.g., oncologist, neurologist, psychiatrist)
    • Include specialist consultation documentation when required
    Prior Authorization

    Xdemvy prescriber requirement

    Xdemvy must be prescribed by or in consultation with an ophthalmologist or optometrist for Demodex blepharitis; coverage duration 2 years.

    • Document diagnosis of Demodex blepharitis
    • Prescriber: ophthalmologist or optometrist or documented consultation
    • Coverage duration: 2 years
    Note

    Part B vs Part D coverage determination

    Submit information describing the use and setting of the drug when requested to determine whether coverage is under Medicare Part B or Part D; failure to provide this may prevent correct coverage determination.

    • Include details of drug use and care setting (infusion center, hospital outpatient, office, home, pharmacy) when requested
    • Failure to submit may affect Part B vs Part D determination and coverage routing
    Step Therapy

    Abilify Mycite: prerequisite therapy — requires use of a prerequisite Part D drug

    Abilify Mycite requires use of a prerequisite Part D drug prior to approval when applicable; providers must document prior Part D therapy per product note.

    • Document use of prerequisite Part D drug as indicated
    • Include prior Part D therapy records with PA request
    Step Therapy

    Various products: prerequisite Part D drug requirement

    Some criteria explicitly require use of a prerequisite Part D drug while others do not; providers must follow the per‑product prerequisite Part D drug flag in the policy when submitting PA requests.

    • Check product entry for 'Criteria DOES require use of a prerequisite Part D drug' or 'Criteria DOES NOT require'
    • Include documentation of prior Part D drug when required
    Step Therapy

    Step/conservative therapy requirements

    Many biologics and specialty agents require failure, contraindication, or intolerance to specified topical, conventional, or biologic therapies prior to approval; document trials and outcomes (duration, doses, reasons for discontinuation) as required.

    • Document trial and failure/contraindication/intolerance to specified prior therapies (e.g., topical corticosteroids, NSAIDs, methotrexate)
    • Provide duration and clinical response details to prior therapies
    Step Therapy

    Multiple products: prerequisite Part D drug flags

    Multiple product entries explicitly note whether a prerequisite Part D drug is required; verify the product‑specific flag and provide prior therapy documentation or an attestation if trials are not feasible.

    • Verify 'Criteria DOES require use of a prerequisite Part D drug' in the product entry
    • Attach prior therapy documentation or prescriber attestation if trials are inappropriate
    Step Therapy

    Prerequisite therapy requirements (various)

    Several products require prior trials or failures of specified therapies (examples include hydroxyurea for polycythemia vera, BTK inhibitors for mantle cell lymphoma, gabapentin for lidocaine patches); include prior therapy details in PA submission.

    • List prior therapies tried, durations, responses, and reasons for discontinuation
    • Ensure documented failure/intolerance meets the product's specified requirement
    Note
    Note
    Step Therapy

    Topical retinoid age-based requirement

    Topical retinoids: authorization not required for patients 25 years or younger; for older patients, prior topical treatments are expected and PA applies.

    • If patient >25 years, document prior topical therapies and responses
    • No PA required for patients ≤25 years for topical retinoids
    Documentation Required

    General required medical information

    Providers must submit documented diagnosis and the product‑specific required medical information (e.g., mutation status, prior therapy history, monitoring plans) listed under 'Required Medical Information' for each drug; missing documentation may delay or trigger denial.

    • Include diagnosis, relevant mutation or biomarker results, prior therapy details, and monitoring plans as listed per product
    • Ensure documentation aligns with the product's 'Required Medical Information' section
    Documentation Required

    Ensacove documentation

    For Ensacove, submit NSCLC diagnosis with ALK rearrangement and documentation that the patient has not previously received an ALK‑inhibitor.

    • Document NSCLC with ALK rearrangement
    • Confirm no prior ALK‑inhibitor exposure
    Documentation Required

    For Exkivity: documented diagnosis of locally advanced/metastatic NSCLC with EGFR exon 20 insertion and progression on or after platinum-based chemotherapy

    For Exkivity, provide documentation of locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutation and progression on or after platinum‑based chemotherapy; prescriber must be an oncologist.

    • Provide EGFR exon 20 insertion test results and disease stage
    • Document progression on or after platinum‑based chemotherapy
    • Prescriber: oncologist
    Documentation Required

    For Fasenra: documented diagnosis of severe eosinophilic asthma or EGPA

    For Fasenra, document severe asthma with eosinophilic phenotype despite inhaled corticosteroid plus an additional controller OR EGPA; prescriber must be an asthma specialist or rheumatologist.

    • Document severe eosinophilic asthma phenotype and current controller therapy (ICS + additional controller) or diagnosis of EGPA
    • Prescriber: asthma specialist (allergist, immunologist, pulmonologist) or rheumatologist
    Documentation Required

    Genotropin pediatric GHD initiation: required documentation

    For Genotropin pediatric GHD initiation, submit X‑ray confirming open epiphyses, results of at least two GH stimulation tests showing failure to respond, delayed bone age, and height >2 SD below mean; include relevant conditions and prescriber details.

    • X‑ray showing open epiphyses
    • Results of ≥2 GH stimulation tests showing failure to respond
    • Document delayed bone age and height >2 SD below mean
    • Prescriber and specialty as indicated
    Documentation Required

    Hematologic/immune diagnoses and prior therapy documentation

    For hematologic and immune indications (e.g., chronic GVHD, myelofibrosis, PV), document diagnosis and prior therapy failures as specified (number and types of prior lines); for myelofibrosis reauthorization, include evidence of spleen size reduction or symptomatic improvement.

    • Document diagnosis and prior systemic therapies (number and agents)
    • For myelofibrosis reauth, provide spleen size reduction or symptomatic improvement data
    Documentation Required

    Lymphoma/leukemia prior therapies

    For lymphoma/leukemia agents (e.g., Jubbonti), document relapsed/refractory disease and prior systemic therapies including BTK inhibitor exposure where required.

    • Document relapsed/refractory mantle cell lymphoma or CLL/SLL per criteria
    • List prior systemic therapies and evidence of BTK inhibitor exposure
    Documentation Required

    Prior therapy and monitoring

    Document prior therapies and monitoring as specified for agents such as denosumab, Jynarque, and others; include monitoring schedules and duration where required to support authorization.

    • Provide prior therapy trial details and monitoring results per product (e.g., liver enzyme schedule for Jynarque)
    • Include durations and dates of monitoring tests
    Documentation Required

    Refractory CMV documentation

    For Livtencity, document member weight ≥35 kg and post‑transplant CMV infection/disease refractory to ganciclovir, valganciclovir, cidofovir, or foscarnet (with or without genotypic resistance).

    • Document weight ≥35 kg
    • Provide evidence of refractory CMV after listed antivirals (± genotypic resistance)
    Documentation Required

    Lynparza documentation

    For Lynparza, include documentation of BRCA/HRR mutation status and prior lines of therapy as specified by the cancer indication; prescriber must be an oncologist for certain indications.

    • Attach germline/somatic BRCA or HRR mutation test results
    • Document prior chemotherapy/endocrine therapy timelines as required
    • Prescriber: oncologist for indicated uses
    Documentation Required

    Lytgobi documentation

    For Lytgobi, document previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma with FGFR2 fusions or rearrangements and prescriber involvement by an oncologist.

    • Provide FGFR2 fusion/rearrangement testing results
    • Document prior treatment history
    • Prescriber: oncologist or consultation with one
    Documentation Required

    CF and mutation documentation

    For Orkambi, submit documented diagnosis of cystic fibrosis and confirmation that the member is homozygous for the F508del mutation.

    • Document CF diagnosis
    • Provide genetic testing showing homozygous F508del mutation
    Documentation Required

    Otezla diagnosis and prescriber

    For Otezla, document the specific diagnosis (PsA, PsO, Behcet's) and prior topical/systemic therapy failures as specified; prescriber should be or consult a dermatologist or rheumatologist.

    • Document diagnosis per indication and prior therapy failures
    • Prescriber: dermatologist or rheumatologist or documented consultation
    Documentation Required

    Pemazyre diagnosis

    For Pemazyre, document unresectable, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement and prior treatment history; prescriber must be an oncologist.

    • Provide FGFR2 fusion/rearrangement results and prior treatment documentation
    • Prescriber: oncologist
    Documentation Required

    Documentation must include mutation status (IDH1) for relevant agents

    Documentation must include IDH1 mutation status for AML indications and details about treatment intent (monotherapy or combination with azacitidine) and patient fitness for intensive induction chemotherapy where applicable.

    • Provide IDH1 mutation test results
    • Specify intended use (monotherapy vs combination with azacitidine) and patient fitness for intensive chemo
    Documentation Required

    For EGFR‑ or MET‑altered NSCLC agents: tumor mutation documentation

    For EGFR‑ or MET‑altered NSCLC agents, include tumor mutation status (EGFR exon 19/21 or T790M; MET exon 14 skipping) in the submission to support eligibility.

    • Attach tumor mutation test results (EGFR exon 19/21, T790M; MET exon 14 skipping)
    • Include disease stage and prior therapy information as applicable
    Documentation Required

    Cystic Fibrosis — required documentation

    For cystic fibrosis initial requests (Trikafta/Truqap), document CF diagnosis and at least one CFTR mutation (F508del OR a CFTR mutation responsive based on clinical/in vitro data); include age/formulation limits and that the prescriber is a pulmonologist or CF specialist; coverage duration 2 years.

    • Document CF diagnosis and qualifying CFTR mutation
    • Provide age/formulation details (granules 2–<6 y; tablets ≥6 y)
    • Prescriber: pulmonologist or CF care center specialist
    • Coverage duration: 2 years
    Documentation Required

    Breast cancer — required documentation

    For breast cancer agents (e.g., Tukysa), document HR‑positive, HER2‑negative locally advanced or metastatic disease, PIK3CA/AKT1/PTEN alteration, and prior endocrine therapy progression or early recurrence; intended combination with fulvestrant must be documented; coverage duration 2 years.

    • Document HR+/HER2‑ status and PIK3CA/AKT1/PTEN alteration
    • Document progression on endocrine therapy or recurrence within 12 months of adjuvant therapy
    • Document plan to combine with fulvestrant
    Documentation Required

    Rheumatologic and interstitial lung disease — required documentation

    For rheumatologic and interstitial lung disease indications, document the specific diagnosis and required trial/failure/contraindication/intolerance of prior therapies (e.g., biologics, methotrexate, NSAIDs, glucocorticoids) and prescriber specialty; reauthorization requires evidence of clinical response.

    • Document diagnosis (RA, SJIA, PJIA, GCA, SSc‑ILD) and prior therapy trials with durations
    • Provide prescriber specialty consultation documentation (rheumatologist/pulmonologist)
    • For reauth, include objective evidence of clinical response
    Documentation Required

    Required clinical documentation

    Provider must submit documented diagnosis and evidence of specified prior therapies or treatment context per product (examples include VHL diagnosis, PD‑1/PD‑L1 plus VEGF‑TKI exposure for RCC, ALK/ROS1 mutation status for Xalkori); missing these items may lead to denial.

    • Include diagnosis, biomarker/mutation results, and prior therapy history as specified
    • Ensure documentation matches the product's 'Required Medical Information' to avoid denial
    Documentation Required

    Required submission of use and setting

    Information describing the drug's use and the care setting must be submitted when requested to determine whether the drug is covered under Medicare Part B or Part D; failure to provide this may lead to misrouted coverage determination or denial.

    • Describe the use and setting (hospital outpatient, infusion center, office, home, pharmacy)
    • Provide supporting documentation to enable correct Part B vs Part D assignment
    Denial Risk

    Coverage will not be approved for generalized fatigue, jet lag, or sleep-deprivation

    Coverage will be denied for armodafinil/modafinil requests for generalized fatigue, jet lag, or sleep‑deprivation not associated with a covered diagnosis.

    • Do not submit armodafinil/modafinil for generalized fatigue, jet lag, or non‑covered sleep‑deprivation indications
    Denial Risk

    Benlysta will not be approved as monotherapy or in listed excluded conditions

    Benlysta will not be approved as monotherapy, for members with severe active lupus nephritis or severe active CNS lupus, for autoantibody‑negative members, or in combination with other biologics or IV cyclophosphamide.

    • Do not request Benlysta as monotherapy or for excluded conditions
    • Provide autoantibody‑positive test results where applicable
    Denial Risk

    Specific exclusion for Dupixent

    Dupixent will not be approved for relief of acute bronchospasm or status asthmaticus; ensure indication aligns with listed chronic indications and required prior therapy trials.

    • Do not request Dupixent for acute bronchospasm or status asthmaticus
    • Document chronic indication and prior topical/systemic therapy trials
    Denial Risk

    Icatibant exclusion for acquired angioedema or ACE inhibitor use

    Icatibant will be denied for members with acquired angioedema or those concurrently taking an ACE inhibitor; confirm HAE type and laboratory confirmation where required.

    • Do not request icatibant for acquired angioedema or with concurrent ACE inhibitor use
    • Provide laboratory confirmation for HAE Types 1 & 2 when applicable
    Denial Risk

    Iclusig will not be approved for newly diagnosed chronic phase CML

    Iclusig will not be approved for members with newly diagnosed chronic phase CML; ensure resistance/intolerance or T315I status per product criteria before requesting.

    • Do not request Iclusig for newly diagnosed chronic phase CML
    • Provide documentation of resistance/intolerance to prior kinase inhibitors or T315I mutation status as required
    Denial Risk

    Genotype‑based exclusion (Kalydeco)

    Kalydeco is not effective in patients homozygous for the F508del CFTR mutation; such genotype should not be submitted as eligible for Kalydeco.

    • Do not request Kalydeco for patients homozygous for F508del
    • Provide genotype testing results to confirm eligibility
    Denial Risk

    Liver monitoring and impairment — Jynarque denial risk

    For Jynarque initial use, lack of required liver enzyme monitoring (ALT/AST/bilirubin at baseline, 2 and 4 weeks, then monthly for first 18 months, then at least every 3 months) or history of significant liver impairment risks denial.

    • Provide liver enzyme monitoring per schedule and exclude significant liver impairment (other than uncomplicated polycystic liver disease)
    • Failure to document monitoring may lead to denial
    Denial Risk

    Prior therapy exclusion for Mekinist

    Mekinist will not be approved as a single agent for members who have received prior BRAF‑inhibitor therapy; verify prior BRAF‑inhibitor exposure before request.

    • Do not request Mekinist monotherapy if member received prior BRAF‑inhibitor therapy
    • Document prior therapy history
    Denial Risk

    Specific refusal condition — Quinine Sulfate

    Coverage will not be approved for treatment or prevention of nocturnal leg cramps (Quinine Sulfate); do not submit for this indication.

    • Do not request quinine sulfate for nocturnal leg cramps
    Denial Risk

    Concurrent therapy exclusion — Rubraca

    Rubraca will not be approved for concurrent use with other chemotherapy agents; document monotherapy or maintenance context per policy.

    • Do not request Rubraca for concurrent administration with other chemotherapy agents
    • Document maintenance or monotherapy context as specified
    Denial Risk

    Single‑agent induction exclusion — Rydapt

    Rydapt will not be approved as single‑agent induction therapy for AML; for FLT3+ AML first‑line use, it must be combined with standard cytarabine and daunorubicin induction and cytarabine consolidation.

    • Do not request Rydapt as single‑agent induction for AML
    • If used first‑line for FLT3+ AML, document planned combination with standard induction/consolidation
    Denial Risk

    TIRF non‑cancer exclusion

    TIRF products are not covered for any non‑cancer pain indication; ensure requests are for opioid‑tolerant adult cancer patients with documented breakthrough pain.

    • Do not submit TIRF products for non‑cancer pain
    • Document opioid tolerance and cancer‑related breakthrough pain
    Denial Risk

    Tadalafil/Tafinlar specific exclusions

    Tadalafil is excluded from coverage for erectile dysfunction; Tafinlar is not indicated for wild‑type BRAF mutations — verify indication and mutation status before submission.

    • Do not request tadalafil for ED under this benefit
    • Do not request Tafinlar for wild‑type BRAF tumors
    Denial Risk

    Documentation missing for genetic eligibility (CF)

    Lack of documentation of the required CFTR mutation (e.g., F508del or a CFTR mutation responsive to therapy) for cystic fibrosis drugs may trigger denial; include genetic test results.

    • Attach CFTR mutation testing results showing required mutation or responsive mutation data
    • Missing genotype documentation may result in denial
    Denial Risk

    Molecular and prior therapy requirements (breast cancer)

    Absence of documented PIK3CA/AKT1/PTEN alteration or lack of required prior endocrine therapy (where applicable) may trigger denial for the listed breast cancer agent; include molecular testing and prior therapy history.

    • Provide molecular testing results (PIK3CA/AKT1/PTEN)
    • Document prior endocrine therapy and progression or recurrence timeline
    Denial Risk

    Failure to meet step/failure therapy requirements (RA, JIA)

    Failure to document required trials of comparator therapies (e.g., biologics or JAK inhibitors for RA/JIA) — including reasons for failure, intolerance, or contraindication — may trigger denial for rheumatologic products.

    • Document prior trials, durations, and reasons for failure/intolerance/contraindication
    • Include prescriber specialty consultation when required
    Denial Risk

    Missing required diagnosis or prior therapy

    Requests lacking a documented diagnosis that matches the product's required medical information or lacking required prior therapy documentation (e.g., VHL diagnosis, PD‑1/PD‑L1 + VEGF‑TKI exposure for RCC) may be denied.

    • Ensure submitted diagnosis matches the product's 'Required Medical Information'
    • Include prior therapy documentation where specified to avoid denial
    Denial Risk

    Documentation affects coverage determination

    Failure to submit information describing the use and setting of the drug when requested may prevent determination of whether coverage is under Medicare Part B or Part D and could lead to denial or misrouted coverage.

    • Provide use and setting details when requested (e.g., infusion in hospital outpatient vs Part D pharmacy)
    • Omission may lead to coverage routing errors or denial
    Documentation Required

    For Abilify Mycite: documentation of diagnosis and prior oral aripiprazole response

    For Abilify Mycite, include documentation of diagnosis (bipolar I disorder, major depressive disorder, or schizophrenia) and evidence of worsening with oral aripiprazole; prescriber must be a psychiatrist.

    • Document diagnosis and worsening with oral aripiprazole
    • Confirm prescriber is a psychiatrist
    Documentation Required

    For abiraterone: diagnosis and combination therapy documentation

    For abiraterone (Yonsa), document metastatic castration‑resistant prostate cancer or metastatic high‑risk castration‑sensitive prostate cancer and that abiraterone is being used in combination with prednisone; prescriber must be an oncologist or urologist.

    • Document metastatic CRPC or metastatic high‑risk castration‑sensitive prostate cancer
    • Confirm use in combination with prednisone
    • Prescriber: oncologist or urologist
    Documentation Required

    For adalimumab products: documented diagnosis specific to the indication

    For adalimumab products, provide diagnosis specific to the indication (e.g., ankylosing spondylitis, Crohn's disease, moderate‑to‑severe UC, hidradenitis suppurativa, plaque psoriasis with prior topical failure, RA with prior conventional therapy trial/failure); prescriber must be or consult with relevant specialist (dermatologist, gastroenterologist, ophthalmologist, or rheumatologist).

    • Attach diagnosis documentation for the specific indication
    • Include evidence of prior therapy trials or failures where required
    • Document specialist prescriber or consultation
    Documentation Required

    General required medical information (per‑product)

    For listed products, required medical information must include a documented diagnosis per product‑specific indications (e.g., symptomatic/progressive medullary thyroid cancer for Cometriq); include the items enumerated in each product's 'Required Medical Information' when submitting PA.

    • Provide the exact diagnostic and treatment criteria listed under 'Required Medical Information' for the product
    • Omit nothing required by the product entry to avoid delays
    Documentation Required

    Ensacove documentation (NSCLC ALK, no prior ALK‑inhibitor)

    For Ensacove, include NSCLC diagnosis with ALK rearrangement and confirmation that the patient has not previously received an ALK‑inhibitor.

    • Attach ALK rearrangement testing and prior therapy history showing no prior ALK‑inhibitor exposure

    Initial Authorization Conditions

    Reauthorization and Continuation Conditions

    Step Therapy and Prerequisite Drug Requirements

    ProductPrerequisite Part D Drug Required?
    Abilify Mycite (Maintenance & Starter Kits)Yes — Criteria DOES require use of a prerequisite Part D drug.
    Abiraterone (Yonsa)No — Criteria DOES NOT require use of a prerequisite Part D drug.
    Product/IndicationRequired prior therapies (trial and failure)
    Fasenra — Severe eosinophilic asthma or EGPATrial and failure/intolerance/contraindication to inhaled corticosteroid plus an additional controller (LABA, leukotriene modifier, or sustained‑release theophylline) before approval.
    Enbrel/Cosentyx — Plaque psoriasis, PsA, AS, etc.Failure, contraindication, or intolerance to specified topical/conventional therapies (e.g., topical corticosteroids, vitamin D analogs, tazarotene) or trial/failure of one conventional therapy for RA (methotrexate, leflunomide, or sulfasalazine) as specified per indication.
    Lynparza — BRCA/HRR‑related cancersPrior relevant chemotherapy/endocrine therapy as specified per indication (e.g., prior platinum‑based chemotherapy for ovarian maintenance; prior chemotherapy or endocrine therapy for breast cancer) must be documented before approval.
    ProductPrerequisite Part D Drug Required?Example source note
    FasenraYesCriteria DOES require use of a prerequisite Part D drug for severe eosinophilic asthma/EGPA.
    FotivdaYesCriteria DOES require use of a prerequisite Part D drug for type 2 diabetes initial criteria (see product entry).
    FinteplaNoFintepla entry specifies Criteria DOES NOT require use of a prerequisite Part D drug for Dravet/Lennox‑Gastaut syndromes.
    Product (example)Conventional therapies required before biologic/specialty agent
    Rinvoq / other JAK inhibitors — RA, PsA, ASTrial and failure/intolerance of conventional DMARDs (e.g., methotrexate, leflunomide, sulfasalazine) and in many cases inadequate response to one or more TNF inhibitors as specified.
    Topical/GERD agents (Voquezna) — Erosive esophagitis / H. pyloriTrial and failure/contraindication/intolerance to two generic PPIs (for erosive esophagitis) or trial and failure of bismuth quadruple therapy (for H. pylori) before approval.
    Teriparatide / osteoporosis agentsInadequate response to or intolerance of at least one traditional osteoporosis treatment (alendronate, risedronate, zoledronic acid, etc.) is required prior to approval.
    Indication/ProductPrior biologic or conventional therapy trials required
    Rheumatologic indications (e.g., RA, PsA, AS)Trial and failure of conventional therapies (methotrexate, leflunomide, sulfasalazine) and in many cases inadequate response to TNF inhibitors as specified per product.
    Ulcerative Colitis / Crohn's disease agentsInadequate response or intolerance to one or more TNF blockers required; if TNF blockers are clinically inadvisable, at least one approved systemic therapy is expected.
    Plaque psoriasis biologics (Skyrizi, Stelara)Trial, intolerance, or contraindication to specified topical/systemic therapies or prior biologic as listed in product criteria.
    DrugPrior trials required (as listed)
    Stelara / Skyrizi (dermatologic/GI biologics)Trial, intolerance, or contraindication to specified comparators (Yesintek/Steqeyma or topical/systemic therapies) as required per indication.
    Teriparatide / osteoporosis agentsInadequate response to or intolerance of traditional osteoporosis treatments required before approval.
    Lidocaine patchesFailure, adverse reaction, or contraindication to gabapentin required for postherpetic neuralgia or diabetic neuropathy prior to approval.
    Indication/ProductRequired prior therapies (listed)
    Rheumatoid Arthritis (various agents)Trial and failure, contraindication, or intolerance to two of: Enbrel, a formulary adalimumab product, Orencia, Rinvoq, or Xeljanz; or documentation that trials are inappropriate; continuation of prior therapy pathways described.
    H. pylori / Voquezna productsTrial and failure, contraindication, or intolerance to bismuth quadruple therapy required prior to approval.
    Ankylosing spondylitis / ERAMinimum duration one‑month trial and failure, contraindication, or intolerance to two NSAIDs at maximally indicated doses required prior to approval.
    Product/IndicationPrior therapies to document before approval
    Biologics and targeted agents for RA/PSA/ASDocumentation of prior conventional DMARD trials (methotrexate, leflunomide, sulfasalazine) and often prior TNF inhibitor failure/intolerance as specified per product.
    Lynparza (BRCA/HRR indications)Documentation of BRCA/HRR mutation status and prior lines of systemic therapy per indication (e.g., prior platinum chemotherapy for ovarian indications).
    Praluent/Repatha (PCSK9 class)Elevated LDL‑C despite maximally tolerated high‑intensity statin therapy or statin intolerance must be documented prior to approval.

    Key Clinical Coding & Diagnostic Thresholds

    inv-96: Fibrosis stage requirement for Rezdiffra
    Required fibrosis stageFibrosis stage F2 or F3
    Confirmation methodsConfirmed by both a serum biomarker (e.g., ELF or FIB-4) AND an imaging biomarker (e.g., FibroScan, MRI-PDFF), or by one validated composite test (FAST, MAST, MEFIB) or liver biopsy within the past 12 months
    Exclusion for cirrhosisPatient must not have cirrhosis (e.g., decompensated cirrhosis) at baseline
    Prescriber requirementPrescribed by or in consultation with a gastroenterologist or hepatologist
    Reauthorization conditionReauth requires patient demonstrates positive response to therapy and has not progressed to cirrhosis

    Administration Setting and Medicare Coverage Assignment

    Note
    Note

    Terms and Diagnostic Definitions

    inv-192: Cystic fibrosis with Pseudomonas aeruginosa
    DefinitionCystic fibrosis diagnosis AND evidence of Pseudomonas aeruginosa in the lungs
    Coverage duration2 years
    Prerequisite Part D drugCriteria does NOT require use of a prerequisite Part D drug
    Prescriber restrictionNo prescriber restriction specified in entry
    inv-193: Autoantibody-positive SLE
    DefinitionActive, autoantibody-positive systemic lupus erythematosus (e.g., ANA, anti-ds-DNA, anti-Sm)
    Concomitant therapyMember must be concurrently taking standard therapy (e.g., antimalarials, corticosteroids, or immunosuppressives)
    ExclusionsWill not be approved as monotherapy, for autoantibody-negative members, or in combination with other biologics or IV cyclophosphamide
    inv-194: Non-radiographic axial spondyloarthritis
    DefinitionActive non-radiographic axial spondyloarthritis with objective signs of inflammation (e.g., elevated CRP and/or sacroiliitis on MRI) but without definitive radiographic sacroiliac joint structural damage
    Prior therapy requirementMinimum duration 1 month trial and failure, contraindication, or intolerance to two NSAIDs at maximally indicated doses
    Objective inflammation examplesElevated C-reactive protein (CRP) and/or sacroiliitis on MRI
    inv-195: Pediatric growth hormone deficiency (GHD)
    Initiation criteriaNo epiphyseal closure on X-ray AND failure to respond to at least two standard GH stimulation tests AND documented gender-specific delayed bone age AND height >2 SD below mean for age/sex
    Associated conditionsOne of: chronic renal insufficiency prior to transplant, idiopathic short stature, IUGR, Noonan, Prader-Willi, SHOX deficiency, or Turner syndrome
    Continuation documentationMedical history, growth chart, and improvement in annualized pre-treatment growth rate after first 6 months required for continuation
    inv-196: Hereditary Angioedema (HAE)
    Diagnostic confirmationHAE diagnosis with history of ≥1 severe attack in past 6 months; for Types 1 & 2 confirm with laboratory testing (low C4, reduced C1 esterase inhibitor level or function)
    Prescriber restrictionPrescribing physician must be an allergist, hematologist, or immunologist
    ExclusionIcatibant will not be approved for acquired angioedema or concurrent ACE inhibitor use
    inv-197: deleterious or suspected deleterious gBRCA-mutated
    Meaning in policyIndicates deleterious or suspected deleterious germline (g) BRCA mutation status required for specified Lynparza indications (breast, ovarian, pancreatic, prostate)
    Applies toGermline or somatic BRCA mutations as documented in the medical record
    Prescriber requirementPrescriber must be an oncologist for certain Lynparza indications
    inv-198: FGFR2 gene fusions or rearrangements
    DefinitionFGFR2 gene fusions or rearrangements in intrahepatic cholangiocarcinoma qualifying patients for Lytgobi
    Prescriber restrictionPrescribed by or in consultation with an oncologist
    Coverage duration2 years
    inv-199: MASH
    TermMASH = metabolic dysfunction-associated steatohepatitis (formerly NASH)
    Context of useUsed as diagnosis term for Rezdiffra initial criteria (MASH without cirrhosis)
    inv-200: Opioid tolerant
    DefinitionOpioid tolerant: taking around-the-clock opioids such as morphine 60 mg/day oral or more, fentanyl transdermal ≥25 mcg/hr, oxycodone ≥30 mg/day, hydromorphone ≥8 mg/day, or equianalgesic dosing for ≥1 week
    Indication linkageRequired definition for TIRF product coverage (breakthrough cancer pain)
    Age noteFentanyl lozenges approvable for patients ≥16 years; otherwise adult cancer patients
    inv-201: CFTR mutation responsive
    DefinitionA CFTR gene mutation considered responsive based on clinical and/or in vitro data (used to determine eligibility for CF modulators)
    ApplicationRequired for Kalydeco and Truqap initial authorization when genotype not the common F508del homozygous scenario
    inv-202: Bismuth quadruple therapy
    DefinitionBismuth quadruple therapy = bismuth + metronidazole + tetracycline + a proton pump inhibitor
    Use caseDefined prerequisite therapy for Voquezna (H. pylori) when trial and failure is required
    inv-203: Part B vs Part D coverage
    ConceptSome drugs may be covered under Medicare Part B or Part D depending on use and setting
    Provider actionInformation describing the use and setting of the drug may need to be submitted to determine which benefit applies
    ImplicationCoverage determination (Part B vs Part D) depends on clinical context and site of care
    inv-204: Part B vs Part D determination
    DefinitionPart B vs Part D determination = decision based on the drug's use and care setting that assigns coverage responsibility to Medicare Part B or Part D
    Documentation neededRequires submission of information describing use and setting to make determination

    Policy Background and Scope

    Background: This excerpt lists multiple specialty and pharmacy drugs with their medically‑accepted indications, the required documentation for prior authorization (including mutation status or prior therapy where applicable), prescriber specialty restrictions, and typical coverage durations (commonly 2 years). It is an administrative prior authorization guide rather than a clinical practice guideline and is intended to support prescribers and prior authorization reviewers in determining eligibility for coverage.

    Policy Summary
    Payerharvard pilgrim health care
    PolicyPrior Authorization Medical Necessity Guidelines — Partial drug list
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit documented diagnosis and required prior-therapy or mutation testing evidence when requesting prior authorization.
    SourceLink
    On This Page
    Product-specific Coverage CriteriaPrior Authorization, Documentation, and Prescriber RequirementsInitial Authorization ConditionsReauthorization and Continuation ConditionsStep Therapy and Prerequisite Drug RequirementsKey Clinical Coding & Diagnostic ThresholdsAdministration Setting and Medicare Coverage AssignmentTerms and Diagnostic DefinitionsPolicy Background and Scope

    Coverage 2 years; prescriber oncologist.

    Lynparza - prostate: Deleterious or suspected deleterious germline or somatic HRR gene-mutated metastatic castration-resistant prostate cancer progressed after enzalutamide or abiraterone OR deleterious BRCA-mutated mCRPC being used with abiraterone and prednisone/prednisolone.

    Coverage 2 years; prescriber oncologist.

    Prescribed by a pulmonologist or rheumatologist; reauth requires clinical response.